UTHR (United Therapeutics) Tariff Resilience Score: 6/10 (As of Jun. 30, 2026)


UTHR United Therapeutics Corp UTHR
88 GF Score
Price $541.83
GF Value $386.40
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is United Therapeutics Tariff Resilience Score?

United Therapeutics UTHR -0.57% 88 Tariff Resilience Score is 6 as of Jun. 30, 2026. GuruFocus rates UTHR with a GF Score™ of 88/100 and a GF Value™ of $386.40 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,028 Drug Manufacturers companies, United Therapeutics ranks better than 91.15% on this metric.

United Therapeutics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

United Therapeutics has UTHR has some exposure to tariffs due to its global pharmaceutical supply chain. However, its high-value products and potential for alternative suppliers provide some resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes United Therapeutics might have Average Resilient.

United Therapeutics  (NAS:UTHR) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

United Therapeutics Tariff Resilience Score Related Terms

UTHR vs VTRS, NBIX, ZTS: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

United Therapeutics Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Tariff Resilience Score falls into.


UTHR
88GF Score
United Therapeutics Corp UTHR
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
United Therapeutics (UTHR) has a Tariff Resilience Score of 6 as of Jun. 30, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, United Therapeutics ranks #91 out of 1028 companies in the Drug Manufacturers industry, placing it in the top 8.9%.
Is United Therapeutics' Tariff Resilience Score too high?
United Therapeutics' current Tariff Resilience Score is 6. Based on the distribution chart, United Therapeutics ranks #91 out of 1028 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Tariff Resilience Score compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #91 out of 1028 companies for Tariff Resilience Score. This places United Therapeutics in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. United Therapeutics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $386.40, compared to a current price of $541.83 — trading 40.2% above its estimated fair value. The current Tariff Resilience Score is 6. United Therapeutics' overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For United Therapeutics (UTHR), the current Tariff Resilience Score is 6 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is United Therapeutics (UTHR) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of $541.83 is trading 40.2% above its estimated GF Value™ of $386.40. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for UTHR:

  • Tariff Resilience Score: 6
  • GF Value™: $386.40 vs. price of $541.83 (40.2% above fair value)
  • GF Score™: 88/100 with 7 warning signs

No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

United Therapeutics Business Description

Other Exchanges UTH:GermanyU2TH34:Brazil
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score

Get the complete analysis for UTHR

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$541.83
Price
$386.40
GF Value